Adenomyosis: Pathophysiology, Diagnostic Advances, and Therapeutic Options
Adenomyosis Is Not “Just Heavy Periods”
Adenomyosis remains one of the most underappreciated diseases in gynecology. Too often, it is minimized as a source of heavy bleeding or treated as an incidental imaging finding. In reality, adenomyosis is a clinically significant uterine disease associated with dysmenorrhea, chronic pelvic pain, abnormal uterine bleeding, infertility, and frequent coexistence with endometriosis.
Modern literature supports a more complex biologic model involving inflammation, fibrosis, altered myometrial function, and abnormal neurovascular signaling.
At ESSI, we believe adenomyosis should be approached with the same seriousness and sophistication as endometriosis. It is not enough to identify the diagnosis. The real question is how the disease is behaving in that patient, what symptoms it is actually driving, whether endometriosis is also present, and which treatment strategy best matches their anatomy, symptoms, and reproductive goals.
A Disease That Requires Better Phenotyping
One of the most important advances in adenomyosis care is the shift from late, retrospective diagnosis to accurate preoperative evaluation. High-quality transvaginal ultrasound and MRI now allow clinicians to identify adenomyosis before surgery and characterize disease extent in ways that directly influence management. These tools are no longer merely diagnostic—they are central to treatment planning.
That matters because adenomyosis is not one uniform disorder.
-
Some patients have focal disease or adenomyomas.
-
Others have diffuse myometrial infiltration.
-
Some are dominated by heavy bleeding.
-
Others are dominated by pain, pressure, infertility, or overlapping endometriosis.
A modern center must recognize those distinctions, because different phenotypes require different strategies. At ESSI, that phenotyping is fundamental. We do not treat all adenomyosis the same way, because not all adenomyosis behaves the same way.
Why ESSI Looks at Adenomyosis and Endometriosis Together
One of the biggest mistakes in pelvic pain care is separating diseases that commonly coexist. Adenomyosis and endometriosis often occur together, and when they do, patients may have multiple symptom generators at once.
The uterus may be causing severe dysmenorrhea, bleeding, and contractile pain, while extrauterine endometriosis may be contributing to tethering, ovarian fixation, cul-de-sac obliteration, bowel pressure, uterosacral pain, or deep infiltrating disease. Contemporary guidance supports management strategies that take this overlap seriously.
This is where the ESSI model is different. We do not force patients into an artificial choice between “uterine disease” and “pelvic disease.” We recognize that many patients have both. In selected cases, that means dual treatment: excision of endometriosis to address the extrauterine disease burden, combined with a uterus-preserving strategy to address adenomyosis within the uterine muscle. That is not overtreatment. That is anatomically rational treatment.
The Problem With One-Size-Fits-All Treatment
For too long, adenomyosis management has been framed too narrowly. Patients are often offered suppression, observation, or hysterectomy, with limited discussion of phenotype, coexistence of endometriosis, or uterus-preserving alternatives.
Current guideline-based management reflects a broader therapeutic spectrum. Medical therapy remains appropriate for many patients. Hysterectomy remains definitive for some. Yet there is also a major group of patients in between: women who are highly symptomatic, want uterine preservation, may wish to preserve fertility, and need something more than indefinite suppression.
That is where modern interventional treatment becomes especially important.
Microwave Treatment Has Earned a Place in Modern Adenomyosis Care
At ESSI, we consider microwave treatment an evidence-supported, uterus-preserving option for selected patients with symptomatic adenomyosis.
The careful and accurate way to say it is this: microwave ablation is not universally offered in every center, but it is supported by published guidelines, reviews, and clinical studies as an acceptable treatment modality in appropriately selected patients. It should not be casually dismissed as “merely investigational.” That distinction matters. Sometimes treatments are labeled “investigational” simply because they are unfamiliar to a physician or unavailable at a given institution. But that is not the same as saying the treatment lacks evidence. The literature on microwave ablation in adenomyosis has moved beyond that:
-
2023 Canadian Guideline: Includes minimally invasive thermal ablation procedures, including percutaneous microwave ablation, among the options that may be considered for adenomyosis.
-
2021 Narrative Review: Concluded that ultrasound-guided percutaneous microwave ablation is feasible, safe, and effective for adenomyosis and described it as worthy of clinical application and promotion.
-
2015 Scientific Reports Study: Found that ultrasound-guided percutaneous microwave ablation was effective in symptomatic adenomyosis and did not significantly impair ovarian function, supporting consideration of this treatment as an alternative to hysterectomy in women of reproductive age.
-
2026 Randomized Controlled Pilot Study: Comparing microwave ablation with uterine artery embolization found symptom improvement in both groups, with microwave ablation associated with shorter hospitalization and faster return to daily activities.
Taken together, these data support a strong but responsible statement: microwave treatment is an acceptable uterus-preserving option in selected adenomyosis patients, especially when performed in experienced hands and within a thoughtful multidisciplinary framework.
Why Microwave Fits the ESSI Philosophy
Microwave treatment makes biological and clinical sense because adenomyosis is embedded in the uterine muscle. In selected patients, especially those who want to preserve the uterus, an image-guided thermal approach can target adenomyotic tissue without defaulting to hysterectomy.
At ESSI, we do not view microwave treatment as a substitute for surgical expertise. We view it as part of a more advanced toolkit. That distinction is critical.
-
Some patients need medical therapy and monitoring.
-
Some need hysterectomy.
-
Some need excision of severe endometriosis.
-
Some need a more sophisticated dual approach, particularly when adenomyosis and endometriosis are both contributing to symptoms.
That is the kind of individualized planning ESSI is built for.
The ESSI Difference: Treat the Disease That Is Actually There
At ESSI, we believe the goal is not to push one procedure. The goal is to accurately identify all meaningful disease contributors and treat them in a way that maximizes symptom relief, preserves function, and respects fertility goals.
-
If a patient’s uterus is a major driver of pain and bleeding because of adenomyosis, that must be addressed.
-
If that same patient also has deep infiltrating endometriosis, ovarian fixation, bowel pressure, or significant cul-de-sac disease, that must also be addressed.
Too many patients remain symptomatic because only one part of the problem is treated. A patient may undergo endometriosis surgery but continue to suffer from major uterine pain. Another may undergo hysterectomy while endometriosis outside the uterus remains unrecognized. Another may stay on suppression for years while significant structural disease continues to affect quality of life.
At ESSI, we aim to avoid those errors by matching the intervention to the anatomy.
Q&A With Dr. Vidali
Why do so many adenomyosis patients remain symptomatic even after treatment? Because the disease is often oversimplified. Some patients have diffuse uterine pain generators. Others have adenomyosis plus endometriosis. If you treat only one side of that equation, symptoms may persist.
Is microwave treatment experimental? Not in the dismissive sense that some people imply. It is more accurate to say that it is a specialized, evidence-supported uterus-preserving option that is not yet offered everywhere. The literature and current guideline landscape support its role in selected patients.
Who is a good candidate for microwave treatment? A patient with symptomatic adenomyosis who wants uterine preservation and whose disease pattern is favorable for a uterus-sparing interventional approach. Proper imaging and careful selection are essential.
Why does ESSI often talk about adenomyosis and endometriosis together? Because in real patients they often coexist. If adenomyosis is treated but endometriosis remains, or vice versa, the outcome may be incomplete. We believe better outcomes come from understanding the full pelvic disease burden.
What makes the ESSI approach different? We focus on accurate disease mapping, high-level surgical judgment, fertility awareness, and individualized planning. That means we do not force every patient into the same treatment pathway. We build the plan around the patient’s actual anatomy and goals.
References
-
Kho KA, Gingold JA, Shin JH. Adenomyosis Pathophysiology, Diagnostic Advances, and Therapeutic Options. Obstet Gynecol. 2026. PMID: 41926770.
-
Dason ES, Maxim M, Sanders A, et al. Guideline No. 437: Diagnosis and Management of Adenomyosis. J Obstet Gynaecol Can. 2023.
-
Lin CW, et al. Expert Consensus on the Management of Adenomyosis. 2025.
-
Zhang S, Wang K, Di A, Yu D, Yao T. Ultrasound-guided percutaneous microwave ablation of adenomyosis: a narrative review. Ann Palliat Med. 2021.
-
Yang Y, et al. Ultrasound-guided percutaneous microwave ablation for adenomyosis: efficacy of treatment and effect on ovarian function. Sci Rep. 2015.
-
Jonsdottir G, Lantz E, Beermann M, et al. Symptom improvement in adenomyosis patients after ultrasound guided microwave ablation or uterine artery embolization, a randomized controlled pilot study. PLoS One. 2026.
